Press Releases

Therapeutic Solutions International’s Subsidiary OmniBiome, Inc. Announces First Oral Microbiome Therapy for Periodontal Disease

Therapeutic Solutions International Announces the Licensing of Probiotic Technology to OmniBiome, Inc.

Therapeutic Solutions International, Inc. announced today that the Company has licensed an additional Patent to OmniBiome, Inc. (Omni), a wholly owned subsidiary of Therapeutic Solutions International, Inc., focused on Fetal-Maternal Health.

Therapeutic Solutions International Announces the Licensing of Patents to OmniBiome and the Appointment of Iryna Dzieciuch, M.S. as Chief Executive Officer of OmniBiome

Therapeutics Solutions International, Inc. announced today that the Company has licensed three Patents to OmniBiome, Inc. (“OmniBiome”) a wholly owned subsidiary of Therapeutic Solutions International, Inc. (“TSI”) focused on Fetal-Maternal Health, with the Company’s goal to assist women in the treatment or prevention of pre-term birth and pregnancy complications.

Therapeutic Solutions International Files Patent on Cytokine Modulation to Prevent Pregnancy Loss and Pre-Term Labor

Therapeutics Solutions International, Inc., announced today the filing of a patent application covering novel means of modulating the immune system to prevent miscarriages and preterm labor. The filed patent covers utility of vaccines and various agents to alter pathological conditions in which the maternal immune system induces a process of inflammation that culminates in placental alterations leading to either fetal loss or preterm labor. To the knowledge of the company, this is one of the only experimental approaches in development for addressing this unmet medical need.

Therapeutic Solutions International Develops Cytokine Based Diagnostic Test for Preterm Labor and Complications of Pregnancy.